The issue with mass-marketed compounded drugs like Wegovy extends beyond IP infringement. It attacks the fundamental "social contract" of biopharma: companies invest billions in R&D for a period of market exclusivity. Allowing compounded copies to bypass this system erodes the incentive for all future drug development.

Hims & Hers' persistence in selling high-margin compounded GLP-1s, even as shortages ease, is a strategic choice born of necessity. Switching to low-margin branded drugs ($10-15 profit per script) would collapse their business model, making the high-risk strategy a "financial Hail Mary."

The pro-peptide argument isn't that these substances are proven cures, but that a regulated "white market" is safer than the current gray market. By moving production to GMP-certified compounding pharmacies under FDA oversight, the goal is to reduce harm from a dodgy, unregulated supply chain that already exists.

The threat from compounding pharmacies goes beyond patent workarounds. By offering drugs like tirzepatide in custom formulations, they enable flexible microdosing that can reduce side effects and improve patient outcomes. This model of personalization directly challenges the standardized, one-size-fits-all approach of mass-produced pharmaceuticals.

Online vendors legally sell unregulated peptides by labeling them "for research only," while simultaneously providing syringes, tutorials, and marketing that normalizes human injection. This strategy exploits a regulatory loophole to create a thriving market for untested performance-enhancing drugs.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

The Myriad Genetics case made naturally occurring compounds unpatentable. This removed the financial incentive for pharmaceutical companies to spend hundreds of millions on FDA trials for peptides, which are naturally derived. Compounding pharmacies filled the void until a 2023 FDA ban pushed these promising compounds into a risky, unregulated gray market.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

The demand for unregulated peptides isn't just from niche biohackers; it's also from older individuals seeking relief for conditions like chronic joint pain where traditional medicine offers few effective solutions. This highlights a significant unmet need driving patients to experimental substances.